

adjustment of the degree parameter, which helped reduce overfitting and adjust the complexity to the data. In contrast, the Linear kernel remained stable at 0.5600, as its linearity made hyperparameter tuning less impactful. These results confirm that hyperparameter tuning has a greater impact on complex kernels such as RBF and Polynomial than the simpler Linear kernel.

C. Model Validation

Model validation was performed using internal and external approaches. In internal validation, we calculated R_{Train}^2 and Q_{LOO}^2 to measure the performance of the model on training data. While in external validation, R_{Test}^2 is used to measure the generalization of the model on data that has never been seen before. The model is considered feasible if the R^2 and Q^2 score exceed the predefined thresholds of 0.6 and 0.5, respectively. In addition, several other validation metrics are also considered to ensure the quality of the model.

TABLE VII.
CALCULATED STATISTICAL PARAMETERS FOR SVM KERNELS (TRAIN SET)

Parameter	RBF	Linear	Poly	Threshold
R^2	0.8728	0.7762	0.7803	>0.6
Q^2	0.6470	0.6313	0.6108	>0.5
k'	1.0213	1.0260	1.0262	$0.85 \leq k' \leq 1.15$
$\frac{(r^2 - r_0^2)}{r^2}$	0.0053	0.0019	0.0054	<0.1
$ r_0^2 - r'^2 $	0.0386	0.0798	0.0961	<0.3
r_m^2	0.8137	0.7461	0.7297	>0.5
Δr_m^2	0.1223	0.1912	0.1966	<0.2

TABLE VIII.
CALCULATED STATISTICAL PARAMETERS FOR SVM KERNELS (TEST SET)

Parameter	RBF	Linear	Poly	Threshold
R^2	0.5620	0.4869	0.4873	>0.6
Q^2	0.6470	0.6314	0.6108	>0.5
k'	0.9918	0.7282	0.7955	$0.85 \leq k' \leq 1.15$
$\frac{(r^2 - r_0^2)}{r^2}$	0.0106	0.1497	0.2874	<0.1
$ r_0^2 - r'^2 $	0.1561	0.0002	0.1117	<0.3
r_m^2	0.5187	0.3555	0.3049	>0.5
Δr_m^2	0.1829	0.0001	0.1003	<0.2

In In Table VII and Table VIII, the RBF kernel achieved the best performance with R_{Train}^2 of 0.8728, as well as Q_{LOO}^2 of 0.6470, reflecting reliable prediction in leave-one-out (LOO) cross validation, and R_{Test}^2 of 0.5620. While these results demonstrate the model's ability to capture patterns in the training data, the significant decrease in R_{Test}^2 indicates potential overfitting. This discrepancy may arise due to the limited size of the dataset, which may limit the model's ability to generalize to unseen data.

IV. CONCLUSION

This study develops a prediction model using Camel Algorithm (CA) for feature selection and Support Vector Machine (SVM) equipped with hyperparameter tuning to

predict Angiotensin Converting Enzyme (ACE) Inhibitors as antihypertensive drugs. Feature selection with CA improves model efficiency by filtering out relevant features, while hyperparameter tuning ensures optimal parameters, such as gamma and C in the RBF kernel, resulting in the best performance with R_{Train}^2 of 0.8728 and R_{Test}^2 of 0.5620. This study demonstrates the effectiveness of Camel Algorithm in optimizing feature selection and improving model efficiency. However, the validation results highlighted the potential for overfitting, which can be addressed by applying techniques such as hyperparameter regularization and combining cross-validation with larger datasets. These approaches will not only reduce the risk of overfitting but also improve the model's ability to generalize to unseen data. In addition, exploration of additional validation metrics, such as RMSE or MAE, can provide a more comprehensive evaluation of model performance. Further development is needed, including the use of larger data sets and the exploration of other algorithms, so that this methodology can pave the way for further advances in drug discovery and antihypertensive therapy.

REFERENCES

- [1] A. Wicaksono, Y. I. Listyana, A. A. M. Kesuma, and H. N. N. Fauziyah, "Resiko Penggunaan Captopril terhadap Kejadian Batuk Kering pada Pasien Hipertensi," vol. 5, 2021.
- [2] J. P. Kalehoff and S. Oparil, "The Story of the Silent Killer: A History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debates," *Curr Hypertens Rep*, vol. 22, no. 9, p. 72, Sep. 2020, doi: 10.1007/s11906-020-01077-7.
- [3] P. N. Puspitasari, "Hubungan Hipertensi Terhadap Kejadian Stroke," *jiskh*, vol. 12, no. 2, pp. 922–926, Dec. 2020, doi: 10.35816/jiskh.v12i2.435.
- [4] R. H. Fagard and V. A. Cornelissen, "Effect of exercise on blood pressure control in hypertensive patients," *European Journal of Cardiovascular Prevention & Rehabilitation*, vol. 14, no. 1, pp. 12–17, Feb. 2007, doi: 10.1097/HJR.0b013e3280128bbb.
- [5] J. Dong, S. Wang, X. Yin, M. Fang, Z. Gong, and Y. Wu, "Angiotensin I converting enzyme (ACE) inhibitory activity and antihypertensive effects of rice peptides," *Food Science and Human Wellness*, vol. 11, no. 6, pp. 1539–1543, Nov. 2022, doi: 10.1016/j.fshw.2022.06.011.
- [6] R. Chen *et al.*, "Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study," *Hypertension*, vol. 78, no. 3, pp. 591–603, Sep. 2021, doi: 10.1161/HYPERTENSIONAHA.120.16667.
- [7] J. P. Van Kats, M. A. D. H. Schalekamp, P. D. Verdouw, D. J. Duncker, and A. H. J. Danser, "Intrarenal angiotensin II: Interstitial and cellular levels and site of production," *Kidney International*, vol. 60, no. 6, pp. 2311–2317, Dec. 2001, doi: 10.1046/j.1523-1755.2001.00049.x.
- [8] E. Crouchet *et al.*, "Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation," *JCI*

- Insight*, vol. 7, no. 13, p. e159254, Jul. 2022, doi: 10.1172/jci.insight.159254.
- [9] S. Medjebbar *et al.*, “Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers,” *Onc Immunology*, vol. 9, no. 1, p. 1836766, Jan. 2020, doi: 10.1080/2162402X.2020.1836766.
- [10] D. Wei, W. Fan, and Y. Xu, “In Vitro Production and Identification of Angiotensin Converting Enzyme (ACE) Inhibitory Peptides Derived from Distilled Spent Grain Prolamin Isolate,” *Foods*, vol. 8, no. 9, p. 390, Sep. 2019, doi: 10.3390/foods8090390.
- [11] S. Vegter and L. T. W. De Jong-van Den Berg, “Misdiagnosis and mistreatment of a common side-effect – angiotensin-converting enzyme inhibitor-induced cough,” *Brit J Clinical Pharma*, vol. 69, no. 2, pp. 200–203, Feb. 2010, doi: 10.1111/j.1365-2125.2009.03571.x.
- [12] M. A. Elaziz, A. A. Hemedan, M. Ostaszewski, R. Schneider, and S. Lu, “Optimization ACE inhibition activity in hypertension based on random vector functional link and sine-cosine algorithm,” *Chemometrics and Intelligent Laboratory Systems*, vol. 190, pp. 69–77, Jul. 2019, doi: 10.1016/j.chemolab.2019.05.009.
- [13] Y.-T. Wang, D. P. Russo, C. Liu, Q. Zhou, H. Zhu, and Y.-H. Zhang, “Predictive Modeling of Angiotensin I-Converting Enzyme Inhibitory Peptides Using Various Machine Learning Approaches,” *J. Agric. Food Chem.*, vol. 68, no. 43, pp. 12132–12140, Oct. 2020, doi: 10.1021/acs.jafc.0c04624.
- [14] S. Shah *et al.*, “2D-QSAR Modeling of Chalcone Analogues as Angiotensin Converting Enzyme Inhibitor,” *Biointerface Res Appl Chem*, vol. 13, no. 4, p. 370, Oct. 2022, doi: 10.33263/BRIAC134.370.
- [15] L. Wang, D. Niu, X. Wang, J. Khan, Q. Shen, and Y. Xue, “A Novel Machine Learning Strategy for the Prediction of Antihypertensive Peptides Derived from Food with High Efficiency,” *Foods*, vol. 10, no. 3, p. 550, Mar. 2021, doi: 10.3390/foods10030550.
- [16] T. Yu, C. Nantasenamat, N. Anuwongcharoen, and T. Piacham, “Machine Learning Approaches to Investigate the Structure–Activity Relationship of Angiotensin-Converting Enzyme Inhibitors,” *ACS Omega*, vol. 8, no. 46, pp. 43500–43510, Nov. 2023, doi: 10.1021/acsomega.3c03225.
- [17] S. Shah *et al.*, “*In silico* study to recognize novel angiotensin-converting-enzyme-I inhibitors by 2D-QSAR and constraint-based molecular simulations,” *Journal of Biomolecular Structure and Dynamics*, vol. 42, no. 5, pp. 2211–2230, Mar. 2024, doi: 10.1080/07391102.2023.2203261.
- [18] D. M. Utama, W. O. N. Safitri, and A. K. Garside, “A Modified Camel Algorithm for Optimizing Green Vehicle Routing Problem with Time Windows,” vol. 24, no. 1, 2022.
- [19] M. K. Ibrahim and R. S. Ali, “Novel Optimization Algorithm Inspired by Camel Traveling Behavior,” 2016.
- [20] D. A. Anggoro and D. Permatasari, “Performance Comparison of the Kernels of Support Vector Machine Algorithm for Diabetes Mellitus Classification,” *International Journal of Advanced Computer Science and Applications*, vol. 14, no. 1, 2023.
- [21] D. A. Pisner and D. M. Schnyer, “Support vector machine,” in *Machine Learning*, Elsevier, 2020, pp. 101–121. doi: 10.1016/B978-0-12-815739-8.00006-7.
- [22] D. C. Toledo-Pérez, J. Rodríguez-Reséndiz, R. A. Gómez-Loenzo, and J. C. Jauregui-Correa, “Support Vector Machine-Based EMG Signal Classification Techniques: A Review,” *Applied Sciences*, vol. 9, no. 20, p. 4402, Oct. 2019, doi: 10.3390/app9204402.
- [23] I. Kurniawan, M. S. Fareza, and P. Iswanto, “CoMFA, Molecular Docking and Molecular Dynamics Studies on Cycloguanil Analogues as Potent Antimalarial Agents,” *Indones. J. Chem.*, vol. 21, no. 1, p. 66, Sep. 2020, doi: 10.22146/ijc.52388.